Website Not Compatible with Internet Explorer
Enabling Precision Medicine for Cardiovascular Disease
FDA-cleared and CE-marked cardiovascular diagnostic image analysis software
vascuCAP is the only software developed and validated in histopathology to evaluate atherosclerotic plaque stability from a single CT Angiography to inform risk of event (MACE or Stroke) and treatment selection
FDA-Cleared, CE-Marked, & Reimbursed
Informing Stoke Risk & Treatment Determination
Informing Risk of MACE & Treatment Determination
The vascuCAP® Advantage
Accuracy
(1)
standard care
vascuCAP®
1
(1)
-
Over 40% improvement in stroke prediction accuracy over stenosis-based guidelines
-
Over 30% improvement in MACE prediction accuracy over current standard of care
(2)
1. As presented at Society for Vascular Surgery conference 2020, "CRISP" trial interim results
2. “Automated plaque analysis for the prognostication of major adverse cardiac events” European Journal of Radiology
Cost-Effectiveness
(1)
standard care
vascuCAP®
-
Reimbursement for both workflows
-
Reduction in unnecessary, invasive diagnostics that do not need to intervention
(1) Potential after 1 year when compared to standard care for total health care system due to better outcomes, reduction in overtreatment, and increased provider efficiency
Experience
standard care
vascuCAP®
-
Increased provider efficiency through easy-to-digest chart and narrative reports
-
On-premise software analyzes in minutes
-
Better informed decision-making to improve patient outcomes
-
Non-invasive procedure reduces patient burden & time spent in facility
plaque morphology software
atherosclerotic plaque software
high-risk plaque software
plaque quantification software
atherosclerotic plaque quantification software
Research Edition
Arterial analysis software with innovative additional features for research and studies
